Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy

Overview

Journal JACC CardioOncol

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 6

PMID 39239344

Authors

Katelyn M Atkins

Samuel C Zhang

Christopher Kehayias

Christian Guthier

John He

Jordan O Gasho

Mina Bakhtiar

Katrina D Silos

David E Kozono

Paul C Zei

Anju Nohria

Andriana P Nikolova

Raymond H Mak

Affiliations

Soon will be listed here.

Abstract

Background: Arrhythmias are common following radiotherapy for non-small cell lung cancer.

Objectives: The aim of this study was to analyze the association of distinct arrhythmia classes with cardiac substructure radiotherapy dose.

Methods: A retrospective analysis was conducted of 748 patients with locally advanced non-small cell lung cancer treated with radiotherapy. Cardiac substructure dose parameters were calculated. Receiver-operating characteristic curve analyses for predictors of Common Terminology Criteria for Adverse Events grade ≥3 atrial fibrillation (AF), atrial flutter, non-AF and non-atrial flutter supraventricular tachyarrhythmia (SVT), bradyarrhythmia, and ventricular tachyarrhythmia (VT) or asystole were calculated. Fine-Gray regression models were performed (with noncardiac death as a competing risk).

Results: Of 748 patients, 128 (17.1%) experienced at least 1 grade ≥3 arrhythmia, with a median time to first arrhythmia of 2.0 years (Q1-Q3: 0.9-4.2 years). The 2-year cumulative incidences of each arrhythmia group were 8.0% for AF, 2.7% for atrial flutter, 1.8% for other SVT, 1.4% for bradyarrhythmia, and 1.1% for VT or asystole. Adjusting for baseline cardiovascular risk, pulmonary vein (PV) volume receiving 5 Gy was associated with AF (subdistribution HR [sHR]: 1.04/mL; 95% CI: 1.01-1.08; = 0.016), left circumflex coronary artery volume receiving 35 Gy with atrial flutter (sHR: 1.10/mL; 95% CI: 1.01-1.19; = 0.028), PV volume receiving 55 Gy with SVT (sHR: 1.03 per 1%; 95% CI: 1.02-1.05; < 0.001), right coronary artery volume receiving 25 Gy with bradyarrhythmia (sHR: 1.14/mL; 95% CI: 1.00-1.30; = 0.042), and left main coronary artery volume receiving 5 Gy with VT or asystole (sHR: 2.45/mL; 95% CI: 1.21-4.97; = 0.013).

Conclusions: This study revealed pathophysiologically distinct arrhythmia classes associated with radiotherapy dose to discrete cardiac substructures, including PV dose with AF and SVT, left circumflex coronary artery dose with atrial flutter, right coronary artery dose with bradyarrhythmia, and left main coronary artery dose with VT or asystole, guiding potential risk mitigation approaches.

Citing Articles

Predictors of Atrial Fibrillation After Thoracic Radiotherapy.

Butler S, No H, Guo F, Merchant G, Park N, Jackson S JACC CardioOncol. 2025; 6(6):935-945.

PMID: 39801654 PMC: 11711808. DOI: 10.1016/j.jaccao.2024.08.007.

Elucidating the Signal from the Noise: Mapping Cardiac Conduction Events to Cardiac Substructure Radiation Exposure.

Keane F, Neilan T, Jimenez R JACC CardioOncol. 2025; 6(6):946-948.

PMID: 39801636 PMC: 11711799. DOI: 10.1016/j.jaccao.2024.10.007.

Correction: Cardiotoxicity following thoracic radiotherapy for lung cancer.

Walls G, Bergom C, Mitchell J, Rentschler S, Hugo G, Samson P Br J Cancer. 2025; 132(4):401-407.

PMID: 39775164 PMC: 11833054. DOI: 10.1038/s41416-024-02926-x.

Evaluating the impact of cardiac substructure dosimetric parameters on survival in lung cancer patients undergoing postoperative radiotherapy.

Yilmaz M, Hurmuz P, Gurlek E, Yildiz D, Cengiz M Strahlenther Onkol. 2024; .

PMID: 39641790 DOI: 10.1007/s00066-024-02339-y.

Cardiotoxicity following thoracic radiotherapy for lung cancer.

Walls G, Bergom C, Mitchell J, Rentschler S, Hugo G, Samson P Br J Cancer. 2024; 132(4):311-325.

PMID: 39506136 PMC: 11833127. DOI: 10.1038/s41416-024-02888-0.

References

Tjong M, Zhang S, Gasho J, Silos K, Gay C, McKenzie E . External validation of ardiac disease, ypertension, and ogarithmic eft anterior descending coronary artery radiation dose for predicting major adverse cardiac events after lung cancer radiotherapy. Clin Transl Radiat Oncol. 2023; 42:100660. PMC: 10403724. DOI: 10.1016/j.ctro.2023.100660. View

Walls G, OConnor J, Harbinson M, Duane F, McCann C, McKavanagh P . The Association of Incidental Radiation Dose to the Heart Base with Overall Survival and Cardiac Events after Curative-intent Radiotherapy for Non-small Cell Lung Cancer: Results from the NI-HEART Study. Clin Oncol (R Coll Radiol). 2023; 36(2):119-127. DOI: 10.1016/j.clon.2023.11.029. View

Atkins K, Rawal B, Mak R . Reply: Two Statistical Methodological Issues Worth of Attention for Survival Data Using Multivariable Models. J Am Coll Cardiol. 2019; 74(13):1739. DOI: 10.1016/j.jacc.2019.07.051. View

Gray J, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2019; 15(2):288-293. PMC: 7244187. DOI: 10.1016/j.jtho.2019.10.002. View

Cai G, Li C, Li J, Yang J, Li C, Sun L . Cardiac Substructures Dosimetric Predictors for Cardiac Toxicity After Definitive Radiotherapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2022; 115(2):366-381. DOI: 10.1016/j.ijrobp.2022.08.013. View

Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A . Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020; 31(2):171-190. PMC: 8019325. DOI: 10.1016/j.annonc.2019.10.023. View

McWilliam A, Kennedy J, Hodgson C, Vasquez Osorio E, Faivre-Finn C, Van Herk M . Radiation dose to heart base linked with poorer survival in lung cancer patients. Eur J Cancer. 2017; 85:106-113. DOI: 10.1016/j.ejca.2017.07.053. View

Isensee F, Jaeger P, Kohl S, Petersen J, Maier-Hein K . nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods. 2020; 18(2):203-211. DOI: 10.1038/s41592-020-01008-z. View

Mitchell J, Cehic D, Morgia M, Bergom C, Toohey J, Guerrero P . Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society. JACC CardioOncol. 2021; 3(3):360-380. PMC: 8463721. DOI: 10.1016/j.jaccao.2021.06.003. View

10.

McKenzie E, Zhang S, Zakariaee R, Guthier C, Hakimian B, Mirhadi A . Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617. Int J Radiat Oncol Biol Phys. 2022; 115(5):1138-1143. DOI: 10.1016/j.ijrobp.2022.11.033. View

11.

Yegya-Raman N, Wang K, Kim S, Reyhan M, Deek M, Sayan M . Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC. J Thorac Oncol. 2018; 13(10):1508-1518. PMC: 10905612. DOI: 10.1016/j.jtho.2018.05.028. View

12.

Zhang D, Szymanski J, Bergom C, Cuculich P, Robinson C, Schwarz J . Leveraging Radiobiology for Arrhythmia Management: A New Treatment Paradigm?. Clin Oncol (R Coll Radiol). 2021; 33(11):723-734. DOI: 10.1016/j.clon.2021.09.001. View

13.

No H, Guo F, Park N, Kastelowitz N, Rhee J, Clark D . Predicting Adverse Cardiac Events After Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. JACC CardioOncol. 2024; 5(6):775-787. PMC: 10774791. DOI: 10.1016/j.jaccao.2023.08.007. View

14.

Liu X . Classification accuracy and cut point selection. Stat Med. 2012; 31(23):2676-86. DOI: 10.1002/sim.4509. View

15.

Wang X, Palaskas N, Hobbs B, Abe J, Nead K, Yusuf S . The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers (Basel). 2022; 14(5). PMC: 8909404. DOI: 10.3390/cancers14051304. View

16.

Atkins K, Chaunzwa T, Lamba N, Bitterman D, Rawal B, Bredfeldt J . Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2020; 7(2):206-219. PMC: 7747040. DOI: 10.1001/jamaoncol.2020.6332. View

17.

Loap P, Servois V, Dhonneur G, Kirov K, Fourquet A, Kirova Y . A Radiation Therapy Contouring Atlas for Cardiac Conduction Node Delineation. Pract Radiat Oncol. 2021; 11(4):e434-e437. DOI: 10.1016/j.prro.2021.02.002. View

18.

Wasserthal J, Breit H, Meyer M, Pradella M, Hinck D, Sauter A . TotalSegmentator: Robust Segmentation of 104 Anatomic Structures in CT Images. Radiol Artif Intell. 2023; 5(5):e230024. PMC: 10546353. DOI: 10.1148/ryai.230024. View

19.

McWilliam A, Abravan A, Banfill K, Faivre-Finn C, Van Herk M . Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival. J Thorac Oncol. 2023; 18(5):599-607. DOI: 10.1016/j.jtho.2023.01.085. View

20.

Spigel D, Faivre-Finn C, Gray J, Vicente D, Planchard D, Paz-Ares L . Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(12):1301-1311. PMC: 9015199. DOI: 10.1200/JCO.21.01308. View